Skip to content
CADLCandel Therapeutics, Inc.

Earnings

When Candel Therapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.

26 quarters. Jun 30, 2020 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Mar 11, before the open

Thu, Mar 11, 2027in 114 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 9 – Apr 2

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
—
Revenue, change from a year earlier: Q4 2022 ±0.0%, Q3 2022 ±0.0%, Q2 2022 ±0.0%, Q1 2022 ±0.0%
Net income
-$29.50M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q4 2023—

Latest results

  1. Q3 2026Nov 12, 2026, after the closeThe release
    Revenue
    —
    —
    Net income
    -$21.87M
    N/M
    EPS
    -$0.28
    N/M
    Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced financial results for the third quarter ended September 30, 2026, and provided a corporate update.
  2. Q2 2026Aug 13, 2026, before the openThe release+10.6%by the close of Aug 13
    Revenue
    —
    —
    Net income
    -$38.91M
    N/M
    EPS
    -$0.52
    N/M
  3. Q1 2026May 14, 2026, before the openThe release0.3%by the close of May 14
    Revenue
    —
    —
    Net income
    -$8.86M
    N/M
    EPS
    -$0.14
    N/M
  4. Q4 2025Mar 12, 2026, before the openThe release2.4%by the close of Mar 12
    Revenue
    —
    —
    Net income
    -$29.50M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 12, 2026 · after-hoursNov 12, 202643 d10-Q——-$0.28—
Q2 2026Jun 30, 2026Aug 13, 2026 · pre-marketAug 13, 202644 d10-Q——-$0.52+10.6%
Q1 2026Mar 31, 2026May 14, 2026 · pre-marketMay 14, 202644 d10-Q——-$0.140.3%
FY 2025
Q4 2025derivedDec 31, 2025Mar 12, 2026 · pre-marketMar 12, 202671 d10-K———2.4%
Q3 2025Sep 30, 2025Nov 13, 2025 · pre-marketNov 13, 202544 d10-Q——-$0.216.0%
Q2 2025Jun 30, 2025Aug 14, 2025 · pre-marketAug 14, 202545 d10-Q——-$0.095.8%
Q1 2025Mar 31, 2025May 13, 2025 · pre-marketMay 13, 202543 d10-Q——$0.13+7.5%
FY 2024
Q4 2024derivedDec 31, 2024Mar 13, 2025 · after-hoursMar 13, 202572 d10-K———+9.9%
Q3 2024Sep 30, 2024Nov 14, 2024 · pre-marketNov 14, 202445 d10-Q——-$0.33+0.2%
Q2 2024Jun 30, 2024Aug 13, 2024 · pre-marketAug 13, 202444 d10-Q——-$0.74+4.7%
Q1 2024Mar 31, 2024May 14, 2024 · pre-marketMay 14, 202444 d10-Q——-$0.28+4.9%
Earlier years, FY 2020 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 12, 2026458380
10-QAug 13, 2026347980
10-QMay 14, 2026222904
10-KMar 12, 2026103134
10-QNov 13, 2025279086
10-QAug 14, 2025108450
10-QMay 13, 2025069833
10-KMar 13, 2025038803
10-QNov 14, 2024126767
10-QAug 13, 2024095784

Provenance

ProvenanceData status and checks

Candel Therapeutics, Inc. · CIK 1841387 · Engraved from SEC EDGAR